CLYM Climb Bio Inc

Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.

Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024

Stifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024

36th Annual Piper Sandler Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024

7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at climbbio.com.

About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

InvestorsChris Brinzey ICR Healthcarechris.brinzey@ICRhealthcare.com339-970-2843

MediaJon YuICR Healthcarejon.yu@icrhealthcare.com475-395-5375